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1  | INTRODUC TION
Standard practice patterns for liver transplant recipients include 
multiple immunosuppressive drugs aimed at predetermined trough 
levels, adjusted to time after transplantation. Excellent graft and 
patient survival rates support this approach. However, there are 
significant short‐ and long‐term risks associated with immunosup‐
pression, such as infections, malignancies, cardiovascular disease, 
metabolic disorders, and renal and other complications.1,2
Single‐center reports have demonstrated that many recipients 
can tolerate reduced doses of immunosuppression, suggesting 
that liver transplant recipients are a diverse cohort for whom im‐
munosuppression may be personalized.3‐5 Prospective clinical trials 
report that >40% of highly selected liver transplant recipients can 
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The	 Immune	Tolerance	Network	 ITN030ST	A‐WISH	assessed	 immunosuppression	
withdrawal in liver transplant recipients with hepatitis C or nonimmune nonviral liver 
disease. Of 275 recipients enrolled before transplantation, 95 were randomly as‐
signed 4:1 to withdrawal (n = 77) or maintenance (n = 18) 1‐ to 2‐years posttrans‐
plant. Randomization eligibility criteria included stable immunosuppression 
monotherapy;	adequate	 liver	and	kidney	function;	≤Stage	2	 Ishak	fibrosis;	and	ab‐
sence of rejection on biopsy. Immunosuppression withdrawal followed an 8‐step re‐
duction	algorithm	with	≥8	weeks	per	level.	Fifty‐two	of	77	subjects	(67.5%)	reduced	
to	≤50%	of	baseline	dose,	and	10	of	77	(13.0%)	discontinued	all	immunosuppression	
for	≥1	year.	Acute	rejection	and/or	abnormal	liver	tests	were	treated	with	increased	
immunosuppression; 5 of 32 rejection episodes required a methylprednisolone bolus. 
The composite end point (death or graft loss; grade 4 secondary malignancy or op‐
portunistic	infection;	Ishak	stage	≥3;	or	>25%	decrease	in	glomerular	filtration	rate	
within 24 months of randomization) occurred in 12 of 66 (18%) and 4 of 13 (31%) 
subjects in the withdrawal and maintenance groups. Early immunosuppression mini‐
mization is feasible in selected liver recipients, while complete withdrawal is success‐
ful in only a small proportion. The composite end point comparison was inconclusive 
for noninferiority of the withdrawal to the maintenance group.
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withstand complete withdrawal of immunosuppression when done 
at a mean of 10.2 years after transplantation in adult, and 8.5 years 
in pediatric patients.6,7
The multiple systemic complications that are the direct out‐
comes of standard immunosuppressive regimens continue to justify 
research into the potential elimination of multiple drug use and dose 
minimization. Other options under investigation include substitution 
of current standard immunosuppression with drugs that are less 
toxic, aiming to reduce side effects; however, these drugs may be 
associated with a different range of toxicities.8‐10
The	 Immune	 Tolerance	 Network	 ITN030ST	 A‐WISH	 trial	
(NCT00135694)	was	 a	 prospective	 randomized	 study	 designed	 to	
assess the safety of immunosuppression withdrawal in liver trans‐
plant recipients with hepatitis C or nonimmune nonviral causes of 
liver failure initiated in the first 1‐2 years posttransplantation.
2  | PATIENTS AND METHODS
Subjects were enrolled at 7 liver transplantation centers in the 
United	States	from	November	2005	to	April	2011.	Entry	eligibility	
criteria included the following: liver failure due to infection with the 
hepatitis C virus (HCV), demonstrated by viral genomes in blood; or 
to	nonimmune,	nonviral	(NINV)	causes.
Exclusion criteria included the following: previous, multiorgan, 
or split liver, other than right trisegment, transplant; living or HCV‐
infected donor, or donation after cardiac death; liver failure due to 
autoimmune disease; hepatitis B infection; stage III or higher hepato‐
cellular cancer detected in the explanted liver; and clinically significant 
renal, cardiovascular, or cerebrovascular disease. Subjects with stage 
III or higher cancer in the liver explant were replaced.
All	 subjects	 provided	written	 informed	 consent	 prior	 to	 trans‐
plantation, and again at the point of assessment for randomization 
eligibility. The study protocol conformed to the ethical guidelines of 
the 1975 Declaration of Helsinki and was approved by the institu‐
tional review boards of all participating centers.
2.1 | Study design
Following transplantation, subjects received immunosuppres‐
sion with corticosteroids and a calcineurin inhibitor and/or anti‐
metabolite. Corticosteroids were planned to be tapered within 
3	months.	 At	 6	months	 after	 transplant,	 tacrolimus	 dosing	 was	
adjusted to maintain trough blood levels of 5‐10 ng/mL. Between 
1 and 2 years after transplantation, once eligibility criteria were 
met and at the discretion of the investigator and after review by 
the	study	chair	and	NIH	medical	monitor,	eligible	 subjects	could	
be randomly assigned in a 4:1 ratio to immunosuppression with‐
drawal or to immunosuppression maintenance. Randomization 
was	 stratified	 by	 HCV	 or	 NINV	 stratum.	 Those	 assigned	 to	 im‐
munosuppression maintenance continued study visits for 2 years. 
Those assigned to immunosuppression withdrawal underwent a 
planned taper consisting of eight 8‐week withdrawal steps. The 
initial taper dose was defined as the daily dose at the time of ran‐
dom assignment but with an adjustment to once‐a‐day adminis‐
tration. These subjects continued visits for another 2 years at the 
conclusion of their tapering.
Eligibility for randomization included the following: immunosup‐
pression monotherapy with a calcineurin inhibitor or antimetabolite 
for at least 3 months, Stage 2 (of 6) or less Ishak fibrosis, no post‐
transplant interferon, adequate hepatic and renal function, no biopsy‐
proven rejection within the prior 3 months by local pathology review, 
and absence of Banff moderate or severe acute rejection or chronic 
rejection by central review of a biopsy obtained within 4 weeks.11 
Adequate	hepatic	function	was	defined	for	participants	with	hepatitis	
C infection as total bilirubin of <3 mg/dL and for participants with non‐
immune nonviral causes of liver failure as total bilirubin, alanine ami‐
notransferase	(ALT),	and	alkaline	phosphatase	all	≤2	times	the	upper	
limit of normal.
Those assigned to withdrawal underwent a scheduled taper 
planned	 to	 last	 ≈1	year	with	doses	modified	 in	8‐week	 steps.	 The	
daily baseline immunosuppression dose was initially administered as 
a single morning dose, then reduced to 75%, and then to 50% of the 
baseline dose. This dose was subsequently reduced to every other 
day, biweekly, weekly, and every‐other‐week administration, and fi‐
nally discontinued.
2.2 | Protocol‐specified biopsies
Protocol biopsies were planned for the day of transplant, at eligibility 
for randomization evaluation (12‐24 months posttransplant), and at 
24	and	36	months	posttransplant.	Additional	protocol	biopsies	were	
planned for HCV subjects at 6 and 12 months posttransplant.
2.3 | Allograft dysfunction, resolution, and biopsy
A	liver	biopsy	was	planned	when	allograft	dysfunction	was	detected.	
For HCV subjects, allograft dysfunction was defined as an elevation 
in	aspartate	aminotransferase	(AST)	or	ALT	>3	times	the	upper	limit	
of normal, except during withdrawal when it was defined as >2 times 
the most recent value before a change in immunosuppression. For 
NINV	subjects,	allograft	dysfunction	was	defined	as	an	elevation	in	
aspartate aminotransferase or alanine aminotransferase >2 times 
the	upper	limit	of	normal.	A	biopsy	was	also	performed	when	clini‐
cally indicated at the investigator's discretion. Liver tests (alkaline 
phosphatase,	ALT,	AST,	γ‐glutamyl transferase [GGT], or total bili‐
rubin) were considered resolved when all liver function tests (LFTs) 
were <150% from the higher of the value at randomization or the 
upper limit of normal.
2.4 | Definition and treatment of rejection
Rejection was diagnosed according to Banff criteria.12 Treatment 
was based on the local site pathologist's finding. In order to ensure 
uniformity and comparability with other studies, the study analysis 
was based only on the findings of the central pathologist.
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2.5 | Definition of operational tolerance
Subjects were considered operationally tolerant if they remained off 
immunosuppressive medications for at least 1 year and did not have 
clinical evidence of acute or chronic rejection as determined by liver 
tests.
2.6 | Objectives
The	 A‐WISH	 study	 was	 designed	 to	 determine	 the	 outcomes	 of	
immunosuppression minimization and withdrawal starting within 
2 years after liver transplantation.
2.7 | Study end points
The primary end point was a composite defined as the occurrence of 
death or graft loss, grade 4 secondary malignancy, grade 4 opportunistic 
infection, stage 3 or higher fibrosis, or decrease in renal function. Grades 
for malignancy and opportunistic infection were taken from Common 
Terminology	Criteria	for	Adverse	Events	Version	3.0.	The	end	point	was	
assessed as the occurrence at any time up to 24 months after random 
assignment for all components except for renal function, which was 
assessed using the assessment closest to 24 months up to 36 months 
post–random assignment. Subjects without a renal assessment in this 
range	were	considered	unevaluable	for	the	primary	end	point.	A	decrease	
in renal function was defined as a 25% decrease in glomerular filtration 
rate (GFR) if GFR at randomization was between 30 and 90 mL/min per 
1.732 and a 25% decrease and a GFR <90 mL/min per 1.732 for subjects 
with a GFR >90 mL/min per 1.732 at randomization. The Modification of 
Diet in Renal Disease formula was used to calculate GFR.13 Secondary 
end points were eligibility for random assignment, immunosuppression 
withdrawal completion, immunosuppression‐free duration, hepatitis C 
viral load, fibrosis, and graft loss or death.
2.8 | Sample size
The planned sample size was based on assessment of the primary 
end	point	after	random	assignment	in	the	combined	HCV	and	NINV	
strata and was intended to test whether the withdrawal arm was 
noninferior to the maintenance arm with respect to immunosuppres‐
sion‐related complications.
We intended to enroll enough individuals prior to transplantation 
so that enough patients would be available for the primary comparison 
after accounting for the proportion eligible for random assignment.
The original sample size was 275 subjects with the assumption 
that 75% of those would be eligible for random assignment, allowing 
200 available subjects for the primary comparison. This would have 
allowed an assessment of noninferiority with a 5% margin, a 97.5% 1‐
sided confidence interval, and 80% power with a 10% dropout rate.
However, we observed early in enrollment that only 37% of 
enrolled subjects were in fact eligible for random assignment. We 
therefore re‐estimated the power for the primary comparison. We 
assumed 104 individuals would be available for random assignment. 
This allowed an assessment of noninferiority with a 10% margin, a 
95% 1‐sided confidence interval, and 80% power.
2.9 | Randomization implementation
Subjects were randomly assigned using a random assignment web‐
site hosted by the Data Coordinating Center, RhoFed. Of the 275 
enrolled transplant recipients, 95 were eligible and were randomly 
assigned 4:1 to immunosuppression withdrawal (n = 77) or mainte‐
nance (n = 18) using an allocation sequence developed by the Data 
Coordinating Center.
2.10 | Statistical analysis
Categorical variables were compared using a Fisher's exact test and 
continuous variables were compared between groups using a t‐test 
or Wilcoxon test, depending on normality, with a 2‐tailed 0.05 alpha 
level. Mixed model analyses were used to test for differences among 
the	 treatment	 groups	 for	 longitudinal	 data.	 Analyses	 were	 con‐
ducted	using	SAS	(SAS	Institute	Inc.,	Cary,	NC),	SAS	Institute	Inc.100	
SAS	Campus	DriveCary,	NC	27513‐2414,	USA	version	9.3	or	above.
3  | RESULTS
3.1 | Study subjects
Between	November	 2005	 and	April	 2011,	 286	 consented	 partici‐
pants underwent transplantation at 7 clinical sites (Figure 1). Of 
these, 11 had stage III hepatocellular carcinoma in the explanted 
liver and were excluded without further follow‐up, to achieve the 
target study accrual of 275. The last follow‐up was in September 
2015. Baseline characteristics are in Table S1.
3.2 | Eligibility for random assignment
Of the 275 subjects who continued in the study, 95 subjects (95/275) 
were randomly assigned to immunosuppression withdrawal (30 HCV and 
47	NINV)	or	maintenance	 (7	HCV	and	11	NINV).	One	hundred	eighty	
(93	HCV,	87	NINV)	were	determined	to	be	ineligible	for	random	assign‐
ment (Figure 1). The most common reasons for study termination prior to 
random assignment were voluntary withdrawal in 41 (22.8%) subjects; 
followed by complications related to hepatitis C (such as treatment with 
interferon, fibrosis above stage 2, recurrent or severe hepatitis C, or fibro‐
sing cholestatic hepatitis) in 39 (21.7%); protocol deviations in 19 (10.6%); 
adverse events in 17 (9.4%); and death in 14 (7.8%). There were no dif‐
ferences in baseline characteristics at time of transplant between those 
randomly assigned to the withdrawal or maintenance groups (Table 1).
Ninety‐one	of	95	subjects	were	on	tacrolimus	monotherapy	at	
the time of random assignment. Of the 4 subjects who were not on 
tacrolimus, 2 (1 maintenance, 1 withdrawal) were on cyclosporine 
monotherapy; 1 maintenance subject was on mycophenolic acid 
monotherapy; and 1 withdrawal subject was on mycophenolate 
mofetil monotherapy.
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There	were	 also	 no	 differences	 either	 in	 liver	 tests	 (ALT,	AST,	
alkaline phosphatase, direct bilirubin, GGT) or in immunosuppres‐
sion trough levels at the time of randomization between those ran‐
domly assigned to the withdrawal or maintenance groups (Table 2). 
Furthermore, there were no differences in tacrolimus trough levels 
among sites at the time of random assignment.
A	review	of	the	randomization	eligibility	biopsies	of	the	95	sub‐
jects	who	were	 randomly	assigned	shows	that	6	subjects	 (1	NINV	
subject	in	the	maintenance	group	and	2	HCV	and	3	NINV	subjects	
in the withdrawal group) had findings that were indeterminate/
borderline for acute rejection (Table S2). The incidence of this and 
other findings was similar between the maintenance and withdrawal 
groups.	Although	allowed	by	protocol,	there	were	no	patients	with	
mild rejection in the randomized cohort.
3.3 | Immunosuppression outcomes
3.3.1 | Withdrawal outcomes
Most of the 77 subjects assigned to immunosuppression withdrawal 
achieved substantial reduction in immunosuppression dose while 
maintaining stable allograft function without evidence of clinically sus‐
pected rejection (Figure 2). Seventy‐one (92.2%) tolerated once‐a‐day 
dosing	and	52	(67.5%)	tolerated	a	reduction	to	≤50%	of	baseline	dose.
F I G U R E  1  Disposition	of	enrolled	subjects.	All	subjects	who	were	assessed	for	eligibility	for	random	assignment,	as	well	as	those	who	
were replaced, are included. eGFR, estimated glomerular filtration rate; HCC, hepatocellular carcinoma; HCV, hepatitis C virus
286 
Underwent liver transplantation
275 (130 HCV) 
Continued in the 
trial
11 Were excluded for stage III HCC
18 (7 HCV) 
Were assigned to 
immunosuppression 
maintenance
52 (20 HCV) Had 
minimization to less than 
or equal to 50% of 
baseline
77 (30 HCV) 
Were assigned to 
immunosuppression 
withdrawal
180 (93 HCV) Were not eligible for random assignment
41 (11 HCV) Were voluntarily withdrawn
39 HCV had hepatitis C-related reasons
19 (10 HCV) Had protocol deviations
17 (9 HCV) Had adverse events
14 (8 HCV) Died
8 (3 HCV) Were lost to follow up
42 (13 HCV) Had other reasons (>1 reason can be listed)
16 (8 HCV) Had unknown reasons
15 (3 HCV) Had acute rejection
18 (1 HCV) Were not on monotherapy
4 (0 HCV) Had hepatic function which was not adequate
1 HCV Had eGFR less than 30 mL/min/1.732m2
95 (37 HCV) Were
randomly assigned
25 (10 HCV) Did not 
have minimization to less 
than or equal to 50% of 
baseline
10 (5 HCV) Were 
tolerant
42 (15 HCV) Were not 
tolerant
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3.3.2 | Operationally tolerant subjects
Ten subjects (13.0%) remained off all immunosuppression for at least 
1 year with no clinical evidence of rejection and were termed opera‐
tionally tolerant (Figure 1). We cannot exclude the possibility of sub‐
clinical rejection since biopsies were not available for all operationally 
tolerant subjects (Table 3). Immunosuppression was discontinued 
in these subjects at a median of 33 months (range 28‐44 months) 
from transplantation and 15 months (range 12‐24 months) from 
random	assignment.	Nine	of	these	subjects	remained	off	 immuno‐
suppression therapy for the 2 years of study follow‐up. One subject 
remained off immunosuppression therapy for 14 months but was 
retransplanted due to recurrent hepatitis C.
Laboratory values at the time of randomization and at time of last re‐
port are shown in Figure S1. Laboratory values were available on average 
696 days (range 283‐790 days) following completion of immunosuppres‐
sion	withdrawal.	No	clinical	parameters	assessed	at	time	of	random	assign‐
ment were found to be associated with operational tolerance (Figure S2).
The last available liver function laboratory tests postimmunosup‐
pression withdrawal for the 10 tolerant subjects are shown in Table 3. 
For	NINV	subjects,	ALT	was	normal	or	improved	compared	to	base‐
line in all subjects; GGT was normal or improved except in subject 
212; and alkaline phosphatase was improved or normal in all subjects. 
For	HCV	subjects,	ALT	was	slightly	elevated	compared	to	baseline	in	
106 and 220; GGT was normal in all subjects with assessments; and 
alkaline phosphatase was normal in all subjects except 273.
TA B L E  1   Demographics and baseline characteristics of randomized subjects at transplant
Characteristics Total randomized Maintenance Withdrawal P value
(N = 95) (N = 18) (N = 77)
Age	(y) 54.9 (9.59) 57.4 (7.70) 54.3 (9.92) .21
Sex (male) — n (%) 76 (80.0) 13 (72.2) 63 (81.8) .35
Race — n (%) .31
White 84 (88.4) 17 (94.4) 67 (87.0)
Black 7 (7.4) 0 7 (9.1)
Asian 2 (2.1) 1 (5.6) 1 (1.3)
Other 2 (2.1) 0 2 (2.6)
Donor age (y) 44.7 (17.39) 40.7 (19.79) 45.6 (16.79) .29
Age	matcheda (yes) — n (%) 61 (64.2) 10 (55.6) 51 (66.2) .42
Race matched (yes) — n (%) 59 (62.1) 11 (61.1) 48 (62.3) 1.00
Sex matched (yes) — n (%) 57 (60.0) 8 (44.4) 49 (63.6) .18
BMI (kg/m2) 30.7 (5.42) 30.6 (5.08) 30.8 (5.52) .89
Creatinine (mg/dL) 1.2 (0.65) 1.1 (0.68) 1.3 (0.65) .45
eGFR (mL/min per 1.732) 76.9 (39.47) 85.3 (46.30) 75.0 (37.78) .32
Total bilirubin (mg/dL) 7.3 (9.70) 6.4 (11.78) 7.5 (9.22) .66
HCV viral load (log base 10)
N 14 4 10
Mean (standard deviation) 5.3 (1.18) 5.6 (0.32) 5.2 (1.39) .49
Primary cause of liver disease — n (%)
Chronic hepatocellular disease — 
Hepatitis C
37 (38.9) 7 (38.9) 30 (39.0) 1.00
Chronic	hepatocellular	disease	—	NINVb 58 (61.1) 11 (61.1) 47 (61.0)
Alcoholic	liver	disease 26 (44.8) 4 (36.4) 22 (46.8)
Cryptogenic cirrhosis 6 (10.3) 2 (18.2) 4 (8.5)
Nonalcoholic	steatohepatitis 19 (32.8) 5 (45.5) 14 (29.8)
Metabolic diseases 3 (5.2) 0 3 (6.4)
Hepatocellular carcinoma 3 (5.2) 0 3 (6.4)
Other 1 (1.7) 0 1 (2.1)
Values are expressed as mean (standard deviation), except otherwise noted.
BMI,	body	mass	index;	eGFR,	estimated	glomerular	filtration	rate;	HCV,	hepatitis	C	virus;	NINV,	nonimmune	nonviral.
aSubjects	are	considered	age	matched	if	both	the	recipient	and	donor	are	>55	y	of	age	or	both	are	≤55	y	of	age.	
bNINV	subjects	can	have	more	than	1	primary	reason	for	liver	failure	and	percents	for	subcategories	are	out	of	total	NINV	subjects.	
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Central biopsy findings at the time of random assignment and at 
time	of	last	report	are	also	shown	in	Table	3.	Nine	of	the	10	opera‐
tionally tolerant subjects had a biopsy an average of 212 days (range 
14 to 406 days) following completion of withdrawal; however, 1 of 
these was read locally only with no central reading available. One 
HCV subject had a clinically indicated biopsy 396 days following 
completion of withdrawal with findings of recurrent HCV that ul‐
timately resulted in graft loss. Postimmunosuppression withdrawal 
follow‐up biopsies for the 8 subjects with a central reading available 
demonstrated	stable	findings	in	NINV	subjects	but	some	degree	of	
histologic progression compared to time of randomization in HCV 
subjects, as follows:
1. Increased fibrosis of 1 stage in 3 HCV subjects and from 
stage 1 to stage 5 in 1 HCV subject,
2. Increased periportal/interface hepatitis in 3 HCV subjects and 
stable periportal/interface hepatitis in 2 HCV subjects, and
3. Increased inflammation in 4 HCV subjects.
TA B L E  2   Characteristics of randomized subjects at randomization
Characteristics Total randomized Maintenance Withdrawal P value
(N = 95) (N = 18) (N = 77)
ALT	(U/L) 45.0 (37.93) 57.7 (64.46) 42.1 (28.35) .33
AST	(U/L) 38.8 (30.33) 50.7 (52.86) 36.1 (21.71) .26
Alkaline	phosphatase	(U/L) 107.0 (41.62) 102.1 (36.03) 108.2 (42.95) .58
Direct bilirubin (mg/dL) .93
n 78 15 63
Mean (standard deviation) 0.2 (0.08) 0.2 (0.10) 0.2 (0.08)
GGT (U/L) .28
n 68 13 55
Mean (standard deviation) 75.9 (79.1) 97.5 (100.44) 70.8 (73.34)
Tacrolimus trough levels (ng/mL)
n 90 16 74
Mean (standard deviation) 6.4 (2.35) 6.0 (2.36) 6.5 (2.35) .42
Tacrolimus trough levels by site (ng/mL) .53
Site 1
n 3
Mean (standard deviation) 7.4 (1.66)
Site 2
n 7
Mean (standard deviation) 5.7 (1.09)
Site 3
n 22
Mean (standard deviation) 5.8 (1.42)
Site 4
n 2
Mean (standard deviation) 6.0 (2.26)
Site 5
n 6
Mean (standard deviation) 6.9 (1.90)
Site 6
n 41
Mean (standard deviation) 6.9 (2.99)
Site 7
n 9
Mean (standard deviation) 5.6 (1.82)
Site trough levels were compared using an analysis of variance test.
ALT,	alanine	aminotransferase;	AST,	aspartate	aminotransferase;	GGT,	γ‐glutamyl transferase.
     |  1403SHAKED Et Al.
3.3.3 | Nontolerant subjects
Of the 67 nontolerant subjects, 45 had a biopsy (41 for elevated LFTs 
and 4 for other reasons) at the time of failing withdrawal. Of these 45, 
32 had a finding of rejection (18 mild, 2 mild‐to‐moderate, 9 moderate, 
2 moderate‐to‐severe, and 1 severe) (Figure 3). Immunosuppression 
was increased for all subjects with rejection. Five of the rejection epi‐
sodes also required treatment with at least 1 bolus of methylpredniso‐
lone	500	mg.	No	antibody	treatment	was	administered.	Twenty‐nine	
rejection episodes were considered resolved, ie, with normal LFTs, at a 
median	of	69	days	(range	4‐562	days)	after	failing	withdrawal.	Among	
the 13 subjects with elevated LFTs who had a biopsy where rejection 
was not diagnosed, immunosuppression was nonetheless increased as 
a conservative measure. Liver tests resolved in 11 of these subjects 
in a median of 148 days (range 26‐903 days) after failing withdrawal.
Among	the	22	subjects	who	did	not	have	a	biopsy	at	the	time	of	
failing withdrawal, 19 had elevated LFTs. Of these 19, 12 (63%) re‐
solved in a median of 206 days (range 41‐779 days). Subject‐specific 
information for the nontolerant subjects is in Table S3.
Fifty‐four nontolerant subjects were receiving the same or a 
lower amount of immunosuppression at study completion or termi‐
nation compared to at the time of randomization (Figure 4). Dosing 
information for the 13 who were receiving more immunosuppres‐
sion is shown in Table S4.
Recipients in whom liver enzymes did not return to normal limits 
(NINV	n	=	5,	HCV	n	=	7)	were	not	found	to	have	chronic	allograft	injury	
and/or allograft failure for the postwithdrawal 2‐year observation period.
3.3.4 | Maintenance outcomes
Fifteen of the 18 subjects randomly assigned to maintenance were 
on the same or a lower dose of immunosuppression at their final visit 
compared to randomization (Figure 4). Of the 3 on higher doses, 2 
were no longer on monotherapy and 1 was on an increased total 
dose of a single agent at last follow‐up (Table S4). Regimen changes 
were in response to rejection or elevated liver tests, or to maintain 
within‐range	 trough	 levels.	 All	 maintenance	 subjects	 stayed	 on	
twice‐a‐day dosing. One subject had severe rejection after random 
assignment.
3.4 | Primary end point: clinical complications
A	composite	primary	end	point	was	used	to	assess	whether	immuno‐
suppression withdrawal was at least not inferior to maintenance with 
respect to key posttransplant clinical complications in the 24 months 
after random assignment.
Such clinical complications were identified in 12 (18%, 90% 
confidence interval 10.4‐26.0%) of the 66 evaluable subjects 
assigned to withdrawal and in 4 (31%, 90% confidence interval 
9.7‐51.8%) of the 13 evaluable subjects assigned to maintenance 
(Table 4 and Table S5). This gives a difference between withdrawal 
and	maintenance	of	−13%,	with	a	90%	confidence	interval	of	‐35%	
to 10%. This interval includes both zero and the specified nonin‐
feriority margin of 10%, and therefore renders the findings incon‐
clusive for noninferiority.
3.5 | Rejection and adverse events
Transplant rejection was the most common adverse event in this trial 
reported after random assignment (Table 5 and Table S6) and was 
reported in 31 (40.3%) subjects in the withdrawal group and 1 (5.6%) 
subject in the maintenance group.
Other frequently occurring adverse events included liver func‐
tion abnormalities in 19 (24.7%) subjects in the withdrawal group 
F I G U R E  2   Percent of subjects who 
successfully completed each protocol‐
specified dose reduction. Subjects 
withdrew from immunosuppression 
at protocol‐specified levels with the 
target dose indicated on the horizontal 
axis. Four subjects withdrew off all 
immunosuppression temporarily but 
restarted at a median time of 165 days 
later
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and 2 (11.1%) in the maintenance group and incisional hernia in 6 
(7.8%) subjects in the withdrawal group and 4 (22.2%) subjects in 
the	maintenance	group.	Neoplasms	were	reported	in	16	subjects,	
1 (5.6%) in the maintenance group, and 15 (19.5%) subjects in the 
withdrawal group. Six subjects had grade 4 secondary malignan‐
cies, adverse events that were considered life‐threatening or dis‐
abling, that were counted as events for the primary end point. They 
were 1 lung neoplasm in the maintenance group, and 2 hepatic ma‐
lignant recurrent neoplasms, 1 melanocytic nevus, 1 multiple my‐
eloma, and 1 myelodysplastic syndrome in the withdrawal group. 
Ten subjects had less than grade 4 malignancies, which did not 
contribute to the primary end point. The most frequent were basal 
cell (3) or squamous cell (3) carcinomas. Serious adverse events 
were reported in 43 (55.8%) subjects in the withdrawal group and 
in 7 (38.9%) subjects in the maintenance group (Table S7).
3.6 | Biopsy features in follow‐up
No	differences	between	the	maintenance	and	withdrawal	groups	in	
histological features in liver biopsies were observed in follow‐up bi‐
opsies at a median of 583 days (range 140‐1206 days) after random 
assignment for progression of at least 1 point for fibrosis (50% vs 
31%), periportal/interface hepatitis (17% vs 27%), modified hepatic 
activity index inflammation (25% vs 31%), and steatosis (8% vs 24%); 
nor in the other histological features.
4  | DISCUSSION
This prospective study of 275 liver transplant recipients was de‐
signed to test early immunosuppression minimization and com‐
plete withdrawal in liver transplant recipients receiving standard 
immunosuppression drugs. The study end points were designed to 
determine whether an early decrease of immunosuppression drug 
exposure would reduce the incidence of immunosuppression‐re‐
lated complications and be associated with measurable clinical 
benefits.
A	 key	 aspect	 of	 the	 study	 design	was	 enrollment	 of	 partici‐
pants prior to transplantation. However, only 95 (35%) of the 275 
enrolled met the eligibility criteria for random assignment within 
2 years of transplantation. The 2 leading reasons for discontin‐
uation prior to random assignment were voluntary withdrawal 
(41/180, 23%) or findings related to active HCV infection (39/180, 
22%). In future studies the latter group would more likely be suit‐
able for random assignment given current curative therapy for 
HCV.14,15
Among	77	subjects	randomly	assigned	to	withdrawal,	71	(92%)	
were	able	to	tolerate	once‐a‐day	dosing.	Among	subjects	who	had	
further minimization, 52 (67.5%) were reduced to 50% or less of 
baseline monotherapy dose without any biochemical evidence 
of allograft dysfunction. The study also demonstrates that early 
attempts at complete immunosuppression withdrawal, starting 
in the second year after transplantation, can be tolerated in a T
A
B
L
E
 3
 
La
bo
ra
to
ry
 a
nd
 b
io
ps
y 
fin
di
ng
s 
on
 to
le
ra
nt
 s
ub
je
ct
s 
w
ith
 c
en
tr
al
 re
ad
in
gs
Su
bj
ec
t
St
ra
tu
m
C
om
pl
et
io
n 
of
 IS
 
to
 la
st
 la
bs
 (d
)
La
b 
fi
nd
in
gs
 e
lig
ib
ili
ty
/l
as
t a
va
ila
bl
e
C
om
pl
et
io
n 
of
 IS
 
w
it
hd
ra
w
al
 t
o 
bi
op
sy
 (d
)
C
en
tr
al
 b
io
ps
y 
fi
nd
in
gs
 e
lig
ib
ili
ty
/l
as
t a
va
ila
bl
e
A
LT
 (U
/L
)
G
G
T 
(U
/L
)
A
lk
 P
ho
s 
(U
/L
)
Fi
br
os
is
P
er
ip
or
ta
l/
in
te
rf
ac
e 
he
pa
ti
ti
s
m
H
A
I i
nf
la
m
m
a‐
ti
on
 g
ra
de
St
ea
to
si
s 
se
ve
ri
ty
10
6
H
C
V
79
0
58
/7
1
47
/3
2
84
/5
5
15
6
1/
2
1/
2
3/
5
M
ild
/m
od
er
at
e
14
1
H
C
V
77
2
53
/5
2
60
/2
3
96
/6
5
20
2
0/
1
0/
2
1/
5
M
ild
/m
ild
18
6
H
C
V
73
6
43
/3
3
91
/3
8
90
/7
8
14
1/
1
1/
2
4/
6
M
ild
/m
ild
22
0
H
C
V
74
0
85
/1
01
97
/4
7
10
8/
97
29
1/
2
2/
2
6/
5
N
on
e/
no
ne
27
3
H
C
V
28
3
93
/6
8
32
9/
–
12
5/
16
8
39
6
1/
5
2/
2
7/
9
M
ild
/n
on
e
08
4
N
IN
V
73
5
51
/4
6
26
/2
2
80
/8
7
24
0
0/
0
0/
0
0/
0
Se
ve
re
/s
ev
er
e
09
8
N
IN
V
78
1
17
/3
4
—
/—
11
6/
11
8
27
7a
0/
—
0/
—
0/
—
N
on
e/
—
15
9
N
IN
V
74
7
11
/1
9
23
/2
3
16
0/
52
26
0
0/
0
0/
0
0/
0
M
ild
/m
ild
20
6
N
IN
V
64
6
11
/1
2
9/
41
62
/6
3
—
0/
—
0/
—
0/
—
M
ild
/—
21
2
N
IN
V
72
8
13
/2
9
37
/2
66
12
0/
13
7
40
6
0/
0
0/
0
0/
0
Se
ve
re
/m
od
er
at
e
“—
” I
nd
ic
at
es
 n
ot
 d
on
e.
A
lk
	P
ho
s,
	a
lk
al
in
e	
ph
os
ph
at
as
e;
	A
LT
,	a
la
ni
ne
	t
ra
ns
am
in
as
e;
	G
G
T,
	γ
‐g
lu
ta
m
yl
	t
ra
ns
pe
pt
id
as
e;
	H
C
V
,	h
ep
at
it
is
	C
	v
ir
us
;	
IS
,	i
m
m
un
os
up
pr
es
si
on
;	
m
H
A
I,	
m
od
if
ie
d	
he
pa
ti
c	
ac
ti
vi
ty
	i
nd
ex
;	
N
IN
V
,	n
on
im
m
un
e	
no
nv
ira
l.
a B
io
ps
y 
re
ad
 lo
ca
lly
 o
nl
y 
w
ith
 n
o 
ce
nt
ra
l r
ea
d 
da
ta
 a
va
ila
bl
e.
 
     |  1405SHAKED Et Al.
limited number of recipients who have normal LFTs and no histo‐
logic	 findings	of	 rejection	 in	protocol	biopsies.	A	 limited	number	
of the randomly assigned recipients (10/77, 13%) tolerated com‐
plete withdrawal at a mean of 2.8 years after transplantation. This 
is a unique finding since operational tolerance was achieved very 
early after transplantation using a standard immunosuppression 
strategy.
Previous studies have demonstrated operational tolerance in a 
larger proportion of study subjects; however, these studies enrolled 
stable	 recipients	 long	 after	 the	 transplant	 procedure.	 A	 European	
study enrolled 102 recipients, of whom 40% completed withdrawal 
at a mean of 10.9 years after transplantation, and a smaller US study 
in pediatric recipients of whom 12 of 19 recipients (63%) completed 
withdrawal at a mean of 8.3 years.6,7
The safety of clinically guided minimization and withdrawal must 
be measured against the ability to reverse graft injury. Our study 
and others demonstrate that with careful monitoring, clinical al‐
lograft dysfunction can be reversed with adjustments in immuno‐
suppression management. Liver function at the end of the trial was 
similar between the withdrawal and maintenance groups, suggesting 
F I G U R E  3   Disposition of subjects randomly assigned to immunosuppression withdrawal who were nontolerant. Those with or 
without elevated LFTs, and who did or did not undergo biopsy, are indicated. Those whose elevated LFTs did or did not resolve, and who 
had modification of immunosuppression, are also indicated. LFTs included γ‐glutamyl transferase, alanine aminotransferase, aspartate 
aminotransferase, bilirubin, and alkaline phosphatase. aLFTs are considered elevated if any of the 5 tests were increased >150% from the 
higher of the value at random assignment or the upper limit of normal. LFTs function tests were considered resolved when all tests were 
<150% from the higher of the value at randomization or the upper limit of normal. HCV, hepatitis C virus; IS, immunosuppression; LFTs, liver 
function tests
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that there was no long‐lasting injury related to attempts to minimize 
immunosuppression beyond monotherapy. The recipients in whom 
liver enzymes did not completely return to normal limits were not 
found to have chronic allograft injury and/or allograft failure during 
the 2‐year postwithdrawal observation period.
Allograft	dysfunction	and	clinically	suspected	rejection	with	or	
without biopsy‐proven rejection was reversed by reinstitution of 
calcineurin inhibitors, with few subjects needing steroid therapy, 
and with no clinical evidence of long‐lasting injury to the allograft.
It is likely that minimization or complete withdrawal of immunosup‐
pression can minimize toxicities associated with prolonged exposure 
to high‐dose medications, improve host immune surveillance, improve 
compliance	with	 once‐daily	 dosing,	 and	 reduce	medication	 costs.	A	
recent meta‐analysis in 957 patients demonstrated that lower tac‐
rolimus troughs early after transplant were associated with less renal 
impairment at 1 year without an increase in the rate of rejection.16 
Similarly the rate of recurrence of hepatocellular carcinoma was lower 
in those with less tacrolimus exposure.17
However, previous studies of immunosuppression withdrawal have 
failed to demonstrate such clinical benefit with respect to renal func‐
tion, infection risk, secondary malignancies, or other complications 
related to immunosuppressive medications.6,18‐21 These studies were 
F I G U R E  4   Subject dosing information 
at random assignment and last reported 
follow‐up. The 18 subjects assigned 
to immunosuppression maintenance 
are depicted in the left panel. The 
67 nontolerant subjects and the 10 
tolerant subjects among those assigned 
to immunosuppression withdrawal 
are shown in the middle and right 
panels, respectively. Dosing units are 
as follows: 1 unit is equal to tacrolimus 
1 mg, cyclosporine 100 mg, sirolimus 
1 mg, mycophenolate mofetil 1000 mg, 
mycophenolic acid 720 mg, azathioprine 
50	mg,	or	prednisone	5	mg.	Any	antibody	
use equaled 20 units. Unit scores are 
based on Vasudev et al22
TA B L E  4   Primary end point of immunosuppression complications assessed 2 years after randomization
End point complication Immunosuppression withdrawal Immunosuppression maintenance Differencea
(N = 77) (N = 18)
Evaluable — nb 66 13
One or more immunosuppression 
complications
12 (18%) 4 (31%) −13%	(−35%,	10%)
Death or graft loss 1 (2%) 0
Grade 4 secondary malignancy 4 (6%) 1 (8%)
Grade 4 opportunistic infection 0 0
Stage 3 or higher fibrosis on Ishak scale 3 (5%) 2 (17%)
GFR decreasec 6 (9%) 2 (17%)
aDifference in percentage of subjects with 1 or more immunosuppression complication (withdrawal — maintenance) and corresponding 90% confi‐
dence interval. The confidence interval includes both zero and the noninferiority margin of 10%, so the results are inconclusive. 
bThe primary end point could not be assessed in those subjects who did not undergo complete assessment of outcome measures due to subject non‐
compliance or preference. 
cGFR decrease was defined as a 25% decrease in GFR if GFR at randomization was between 30‐90 mL/min per 1.732 and a 25% decrease and a GFR 
<90 mL/min per 1.732 for subjects with a GFR >90 mL/min per 1.732 at randomization. GFR was calculated using the Modification of Diet in Renal 
Disease formula.5 
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done long after transplantation when drug‐related systemic damage 
with limited reversibility had already been established. In the current 
study we observed a lower but not statistically significant incidence of 
a composite end point related to immunosuppression complications. 
However, the small number of subjects, and small number of events, 
and the relative short‐term follow‐up prevent us from making a con‐
clusion about the impact of early immunosuppression withdrawal on 
such clinical complications.
5  | STUDY LIMITATIONS
Interpretation	 of	 the	 A‐WISH	 trial	 outcomes	 is	 limited	 by	 several	
factors:
1. The trial design overestimated the proportion of participants 
who would be eligible for random assignment. The ability to 
detect differences between the withdrawal and maintenance 
group is therefore limited by the small number who were ran‐
domly assigned, 4:1, to immunosuppression withdrawal vs 
maintenance and by the fact that the maintenance participants 
were followed for only 2 years after random assignment. In 
contrast, the withdrawal participants were followed during the 
withdrawal attempts and then for a further 2 years.
2. The study population included hepatitis C participants with po‐
tentially active disease. This group is now less relevant in clinical 
practice given the current effective treatments for hepatitis C. 
Furthermore, conduct of the trial began in 2005 and continued to 
2014, spanning changing patterns of practice with generally re‐
duced immunosuppression.
3. The use of a composite end point to compare complication rates 
between groups does not allow for direct comparison of individ‐
ual complications. In addition, we were not able to assess the pri‐
mary end point in those participants who did not have complete 
outcome data (specifically, those who declined follow‐up biopsies 
due to clinical stability).
4. The lack of mechanistic results further limits insight into the 
achievement of tolerance among liver transplant recipients.
5. The study design could have been improved by specifying the tim‐
ing of protocol‐mandated biopsies relative to time of completion 
of immunosuppression withdrawal rather than time from 
transplant.
TA B L E  5  Adverse	events	postrandomization	with	an	incidence	>5%
Immunosuppression maintenance 
(N = 18)
Immunosuppression withdrawal 
(N = 77)
Total number of adverse events 54 527
Number	of	subjects	with	at	least	1	adverse	event,	n	(%) 11 (61.1) 72 (93.5)
Infections and infestations, n (%) 5 (27.8) 38 (49.4)
Investigations, n (%) 3 (16.7) 37 (48.1)
Immune system disorders, n (%) 2 (11.1) 31 (40.3)
Gastrointestinal disorders, n (%) 3 (16.7) 26 (33.8)
Metabolism and nutrition disorders, n (%) 3 (16.7) 21 (27.3)
Injury, poisoning, and procedural complications, n (%) 4 (22.2) 19 (24.7)
Musculoskeletal and connective tissue disorders, n (%) 2 (11.1) 20 (26.0)
Nervous	system	disorders,	n	(%) 4 (22.2) 17 (22.1)
General disorders and administration site conditions, n (%) 1 (5.6) 16 (20.8)
Respiratory, thoracic, and mediastinal disorders, n (%) 2 (11.1) 15 (19.5)
Neoplasms	benign,	malignant,	and	unspecified	(incl	cysts	and	
polyps) , n (%)
1 (5.6) 15 (19.5)
Skin and subcutaneous tissue disorders, n (%) 2 (11.1) 11 (14.3)
Hepatobiliary disorders, n (%) 3 (16.7) 8 (10.4)
Renal and urinary disorders, n (%) 0 (0) 10 (13.0)
Vascular disorders, n (%) 0 (0) 10 (13.0)
Psychiatric disorders, n (%) 2 (11.1) 6 (7.8)
Cardiac disorders, n (%) 2 (11.1) 4 (5.2)
Eye disorders, n (%) 0 (0) 5 (6.5)
Surgical and medical  procedures, n (%) 2 (11.1) 3 (3.9)
Reproductive system and breast disorders, n (%) 1 (5.6) 3 (3.9)
The	total	number	of	adverse	events	counts	all	postrandomization	adverse	events	for	all	randomized	subjects.	A	subject	is	counted	once	if	the	subject	
reported	1	or	more	events,	and	percents	are	based	on	the	number	of	subjects	in	the	randomization	group.	Adverse	events	are	coded	according	to	
Medical	Dictionary	for	Regularly	Activities	V11.1.
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6. The per‐protocol definition of operational tolerance did not re‐
quire a biopsy. Thus, some patients who were determined to be 
tolerant did not have protocol biopsies to confirm histological 
characteristics. In addition, in some cases, biopsies intended by 
the protocol were not obtained at the time of abnormal LFTs, due 
to patient noncompliance or preference.
6  | CONCLUSION
We demonstrated that clinically guided minimization can be performed 
in selected patients early after transplantation with manageable risk 
and acceptable safety. We also showed that such minimization within 
the first 2 years after transplantation only rarely results in complete 
immunosuppression withdrawal. In this short follow‐up time there was 
no statistical difference in the primary end point outcome between 
the maintenance and withdrawal groups.
Thus, we conclude that broad‐based immunosuppression with‐
drawal trials conducted early after transplant without specific se‐
lection are unlikely to be successful. However, if biomarkers can be 
defined to guide patient selection to enrich the small population of po‐
tentially tolerant individuals, this approach to early withdrawal could 
be revisited. In addition, we now recognize the challenges inherent in 
attempting to mandate complex patient withdrawal and assessment 
algorithms over many sites, especially in patients with very different 
time courses relative to key clinical milestones.
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